Endovia Health Sciences (EDVA) Capital Expenditures Growth (3y) (2017 - 2023)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Capital Expenditures Growth (3y) (2017 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn | -45.93% |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn | -40.95% |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn | 29.63% |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - | 60.74% |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 27.08% |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -73.58% |
| Jun 30, 2023 | -12.23% |
| Mar 31, 2023 | 63.49% |
| Dec 31, 2022 | 179.97% |
| Sep 30, 2022 | 103.17% |
| Dec 31, 2020 | 100.63% |
| Sep 30, 2020 | -25.12% |
| Jun 30, 2020 | -48.17% |
| Mar 31, 2020 | -47.14% |
| Dec 31, 2019 | -44.45% |
| Sep 30, 2019 | -29.91% |
| Jun 30, 2019 | -33.24% |
| Mar 31, 2019 | -27.96% |
| Dec 31, 2018 | 22.04% |
| Sep 30, 2018 | 60.90% |
| Jun 30, 2018 | 56.86% |
| Mar 31, 2018 | 85.15% |
| Dec 31, 2017 | -2.71% |